- Home
- STRR vs RNAZ Comparison
STRR vs RNAZ Comparison
Compare STRR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRR
- RNAZ
- Stock Information
- Founded
- STRR 1985
- RNAZ 2016
- Country
- STRR United States
- RNAZ United States
- Employees
- STRR N/A
- RNAZ N/A
- Industry
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- STRR Health Care
- RNAZ Health Care
- Exchange
- STRR Nasdaq
- RNAZ Nasdaq
- Market Cap
- STRR 7.0M
- RNAZ 7.2M
- IPO Year
- STRR N/A
- RNAZ 2021
- Fundamental
- Price
- STRR $2.19
- RNAZ $8.08
- Analyst Decision
- STRR
- RNAZ Strong Buy
- Analyst Count
- STRR 0
- RNAZ 1
- Target Price
- STRR N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- STRR 6.2K
- RNAZ 4.3M
- Earning Date
- STRR 03-21-2025
- RNAZ 03-31-2025
- Dividend Yield
- STRR N/A
- RNAZ N/A
- EPS Growth
- STRR N/A
- RNAZ N/A
- EPS
- STRR N/A
- RNAZ N/A
- Revenue
- STRR $50,375,000.00
- RNAZ N/A
- Revenue This Year
- STRR $15.58
- RNAZ N/A
- Revenue Next Year
- STRR $36.27
- RNAZ N/A
- P/E Ratio
- STRR N/A
- RNAZ N/A
- Revenue Growth
- STRR 2.22
- RNAZ N/A
- 52 Week Low
- STRR $2.05
- RNAZ $2.66
- 52 Week High
- STRR $5.35
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- STRR 49.56
- RNAZ 48.31
- Support Level
- STRR $2.10
- RNAZ $10.02
- Resistance Level
- STRR $2.23
- RNAZ $11.30
- Average True Range (ATR)
- STRR 0.10
- RNAZ 1.97
- MACD
- STRR 0.02
- RNAZ -0.18
- Stochastic Oscillator
- STRR 63.64
- RNAZ 26.75
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.